Search results
Results from the WOW.Com Content Network
In this article, we discuss 10 best biotech stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Biotech Stocks To Buy According To Hedge Funds.
In January 2021, Thermo Fisher Scientific announced it had acquired Belgium-based viral vector manufacturer, Henogen SA, from Groupe Novasep SAS for €725 million in cash [57] [58] [59] and point-of-care molecular diagnostics provider Mesa Biotech, Inc. for up to $550 million. [60] [61]
With the lower re-negotiated a lower price of $21.5 billion between Johnson & Johnson and Guidant, Boston Scientific announced an unsolicited offer of $24.6 billion for Guidant (an offer of $72 per share of Guidant, $36 in cash and a fixed number of Boston Scientific shares valued at $36 a share). 26 2006 Johnson & Johnson: Guidant: 24.2 38
A newly minted biopharma initial public offering (IPO) has Wall Street analysts rushing to the gates to price it for massive gains.. Artiva Biotherapeutics (NASDAQ: ARTV) is making waves with its ...
Get breaking Business News and the latest corporate happenings from AOL. From analysts' forecasts to crude oil updates to everything impacting the stock market, it can all be found here.
Robert W. Duggan (born 1944) is an American billionaire entrepreneur, biotech and health care executive. He is the former CEO of biopharmaceutical company Pharmacyclics [2] and was previously CEO of surgical systems maker Computer Motion from 1997 to 2003. [3]
The following table lists the largest biotechnology and pharmaceutical companies ranked by market capitalization in billion US dollars. The change column indicates the company's relative position in this list compared to their relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Patented Medicine Prices Review Board office in Ottawa. Bill C-22, which was passed in 1987, established a compulsory licensing system under which drug patent holders were required to allow competing drug manufacturers to import their patented drug in exchange for a very modest 4% royalty, which resulted in an increase in the market share of generic drugs.